Santen Pharmaceutical Co., Ltd. (SNPHY)

Market Cap	3.42B
Revenue (ttm)	2.04B
Net Income (ttm)	218.28M
Shares Out	n/a
EPS (ttm)	0.63
PE Ratio	15.67
Forward PE	n/a
Dividend	0.25 (2.29%)
Ex-Dividend Date	Sep 29, 2025

Volume	295
Average Volume	3,892
Open	10.82
Previous Close	10.65
Day's Range	10.01 - 10.82
52-Week Range	8.65 - 13.00
Beta	0.19
RSI	49.20
Earnings Date	Nov 6, 2025

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNPHY

Financial Performance

In 2024, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.

Financial numbers in JPY